Notes / Company

Zydus Lifesciences Ltd.

ZYDUSLIFE BSE 532321 ISIN INE010B01027 Pharmaceuticals

Fundamentals

Market cap: ₹1.10 lakh cr
P/E: 21.80×
ROE: 18.89%
Debt / equity: 0.13
Div yield: 0.09%
52-week range: 835.50 — 1126.00

Research on Tijori Finance

Company snapshot

Zydus Lifesciences Ltd.

Pharmaceuticals

₹1.14 L cr

P/E 22.58×

Latest quarter · Mar 2026

Sales₹7,587 cr

Net profit₹1,341 cr

Op. margin+25.2%

EPS₹12.65

Strength & growth

Debt / equity0.13×

Current ratio1.89×

Sales CAGR+11.1%

EPS CAGR+10.0%

The timeline — 3 notes on Zydus Lifesciences Ltd.

July 2026

03 Jul 26 · 12:18 PM IST Brief

Brief · Mega cap

Zydus and Apollo bring Guardant's multi-cancer blood test to India

The Shield test, already exclusive to Zydus, will now screen across Apollo's network. No financial terms disclosed.

June 2026

03 Jun 26 · 10:33 AM IST Lead

Lead · Mega cap

USFDA flags purified talc at Zydus's Baddi plant in Warning Letter

The agency cites a raw-materials failure in a technical review, not a live inspection. The facility already carries a less severe FDA classification.

May 2026

27 May 26 · 5:51 PM IST Lead

Lead · Mega cap

Zydus's US liver drug gets a faster FDA look. A decision comes Nov 2026.

Priority Review trims the standard clock to 8 months. Saroglitazar now has a concrete US timeline.

Verify on exchange BSE filings for ZYDUSLIFE NSE filings for ZYDUSLIFE Tijori Finance company page